Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes
Author(s) -
Andrew A. Pieper,
Daniel J. Brat,
David K. Krug,
Crystal C. Watkins,
Alok Gupta,
Seth Blackshaw,
Ajay Verma,
ZhaoQi Wang,
Solomon H. Snyder
Publication year - 1999
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.96.6.3059
Subject(s) - poly adp ribose polymerase , streptozotocin , islet , diabetes mellitus , polymerase , nad+ kinase , pancreas , endocrinology , medicine , parp inhibitor , pancreatic islets , chemistry , biology , enzyme , biochemistry
Streptozotocin (STZ) selectively destroys insulin-producing beta islet cells of the pancreas providing a model of type I diabetes. Poly(ADP-ribose) polymerase (PARP) is a nuclear enzyme whose overactivation by DNA strand breaks depletes its substrate NAD+ and then ATP, leading to cellular death from energy depletion. We demonstrate DNA damage and a major activation of PARP in pancreatic islets of STZ-treated mice. These mice display a 500% increase in blood glucose and major pancreatic islet damage. In mice with homozygous targeted deletion of PARP (PARP -/-), blood glucose and pancreatic islet structure are normal, indicating virtually total protection from STZ diabetes. Partial protection occurs in PARP +/- animals. Thus, PARP activation may participate in the pathophysiology of type I diabetes, for which PARP inhibitors might afford therapeutic benefit.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom